Medexus Pharmaceuticals Inc is seeing a rise in its stock price, which reflects positive investor sentiment.
In today’s trading session, Medexus Pharmaceuticals Inc (MDP.TO) shares gained 3.81%, closing at CA$4.90. This uptick comes alongside recent corporate developments that are likely attracting investor interest.
Investor takeaway: Keep an eye on Medexus Pharmaceuticals as it continues to show strong product performance, especially with its GRAFAPEX product line.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$148.33M
52W high
$5.50
52W low
$2.51
1W change
-4.30%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP · as of Sep 17, 2026
Wall Street analysts forecast MDP stock price to rise 48.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+48.0% Upside
Current Price
C$4.90
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
27.2%
Annualized
90-Day Vol
38.9%
Annualized
Trend (90d)
-16.0%
Annualized drift
90d Mean
C$4.63
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.81 | C$4.38 – C$5.28 |
| 60 trading days | C$4.72 | C$4.13 – C$5.39 |
| 90 trading days | C$4.63 | C$3.93 – C$5.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medexus Pharmaceuticals Inc Market Cap Reaches CA$148.33 Million
With a market cap of CA$148.33 million, Medexus Pharmaceuticals is still classified as a small-cap stock, which can lead to fluctuations in its stock price.
Bull case
The recent increase in stock price may be linked to the company’s strong quarterly performance, particularly with GRAFAPEX, which has shown promising results in recent reports.
Bear case
Despite the positive movement, investors should be cautious. Medexus Pharmaceuticals currently has a negative profit margin, indicating ongoing financial challenges.
Recent Performance Highlights
Advertisement
Medexus Pharmaceuticals has recently reported its best quarter of product-level performance for GRAFAPEX, likely contributing to the positive stock movement. Investors are responding favorably to these results, showing confidence in the company’s growth potential.
Market Sentiment and Future Outlook
The rise in Medexus Pharmaceuticals' stock price today reflects a broader positive sentiment in the market. However, investors should monitor the company’s financial health, particularly its profit margins, as they consider long-term investment strategies.
Understanding the Risks
While the stock is performing well today, it’s essential for investors to understand the risks of investing in smaller pharmaceutical companies like Medexus. The lack of profitability and market volatility should be considered in any investment decision.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
